EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Brian G Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P De Alwis, Eric Rubin, Alexandra Snyder, Jedd D Wolchok, Antoni Ribas

Cancer Cell · 2023-09 · 41 (9) · 1680-1688.e2

DOI: 10.1016/j.ccell.2023.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023-09. Verfasst von Brian G Topp und 7 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc, Rahway, NJ, USA. Electronic address: brian.topp@merck.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Merck Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellCarcinoma, Transitional CellUrinary Bladder NeoplasmsLung NeoplasmsMelanomaKidney NeoplasmsHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckDisease ProgressionAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

clear-cell renal cell carcinomagastric cancerhead and neck squamous cell carcinomamelanomanon-small cell lung cancerpembrolizumabpostprogression responseurothelial carcinoma

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Merck & Co., Inc, Rahway, NJ, USA. Electronic address: brian.topp@merck.com.
  • Vantage Research, Chennai, India.
  • Merck & Co., Inc, Rahway, NJ, USA.
  • Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • UCLA, Los Angeles, CA, USA.

Förderung

  • NCI NIH HHS
  • Merck Sharp and Dohme

Zitieren

APA

Topp, B. G., Channavazzala, M., Mayawala, K., De Alwis, D. P., Rubin, E., Snyder, A., Wolchok, J. D., & Ribas, A. (2023). Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell, 41(9), 1680-1688.e2. https://doi.org/10.1016/j.ccell.2023.08.004

Vancouver

Topp BG, Channavazzala M, Mayawala K, De Alwis DP, Rubin E, Snyder A, et al. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 2023;41(9):1680-1688.e2. doi:10.1016/j.ccell.2023.08.004

BibTeX
@article{Topp2023,
  author = {Topp, Brian G and Channavazzala, Madhav and Mayawala, Kapil and De Alwis, Dinesh P and Rubin, Eric and Snyder, Alexandra and Wolchok, Jedd D and Ribas, Antoni},
  title = {Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression},
  journal = {Cancer Cell},
  year = {2023},
  volume = {41},
  number = {9},
  pages = {1680--1688.e2},
  doi = {10.1016/j.ccell.2023.08.004}
}
Kostenlos starten →